intra-arterial cocktail therapy

PreclinicalSmall molecule

intra-arterial cocktail therapy is one of 38 small molecule programs targeting Stroke, Ischemic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stroke, IschemicRecruiting

Ischemic StrokeRecruiting

Stroke, IschemicPreclinical

Recruiting

Ischemic StrokePreclinical

Recruiting

Competition

Competitive Landscape

116 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Atorvastatin Calcium

Merck & Co.

Phase 3

1 2

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 3

PCSK9 Inhibitor

YYun Dai Chen

Phase 3

3 4

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

1 5

Aggrastat

MMedicure

Phase 3

4 6

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Phase 3

9 7

Tenecteplase or Alteplase

IInsel Gruppe AG, University Hospital Bern

Phase 3

2 8

Proamatine

Takeda

Preclinical

2 9

Levaquin

WWim Janssens

Preclinical

3 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Ischemic Stroke

NCT04664946

PreclinicalRecruiting

Stroke, Ischemic

NCT04664933

PreclinicalRecruiting

Ischemic Stroke

NCT04201964

Clinical

Trials by Indication[1]

Ischemic stroke3 trials

Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT)

Completed·HHui-Sheng Chen·N/A·NCT04202549·30 enrolled

Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK): a Prospective, Single Arm, Pilot Study

Recruiting·HHui-Sheng Chen·Preclinical·NCT04201964·30 enrolled

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT): One Single Center, Safety and Feasibility Study

Recruiting·HHui-Sheng Chen·Preclinical·NCT04664946·30 enrolled

Stroke, Ischemic1 trial

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET): One Single Center, Safety and Feasibility Study

Recruiting·HHui-Sheng Chen·Preclinical·NCT04664933·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for intra-arterial cocktail therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intra-arterial cocktail therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intra-arterial cocktail therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hui-Sheng Chen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHui-Sheng Chen

intra-arterial cocktail therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Ischemic stroke3 trials

Stroke, Ischemic1 trial

References

Drug Info

Quick Facts

Related News